Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Property, Plant, and Equipment (Net)

Last Annual Value

695.06K

3-Year CAGR

-11%

5-Year CAGR

42%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Property, Plant, and Equipment (Net)

NTRB · NASDAQ
CompanyProperty, Plant, and Equipment (Net)
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
695.06K
-4.8%-7.0%N/A 
0.00
N/AN/AN/A
0.00
N/AN/AN/A
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
23.13M
-2.4%-4.0%-2.6%
7.42M
-2.1%5.1%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
28.48M
-13.6%-4.0%11.0%
409.01K
-11.3%-16.5%N/A
16.26M
14.9%31.9%58.5%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
25.85M
-10.9%5.5%62.6%
IMA logo
ImageneBio Inc
NASDAQ:IMA
0.00
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
1.18M
-12.5%1.5%-7.2%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15